Results 201 to 210 of about 77,800,290 (253)
Concurrent Inhibition of AKT and GLUT1 Reveals Endpoint-Specific Effects on Glucose Metabolism and Cell Death in HepG2 Hepatocyte-Derived Cells. [PDF]
Asiri A +9 more
europepmc +1 more source
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li +11 more
wiley +1 more source
Monocarboxylate transporter 1 deficiency: a rare case report and systematic review of genetically confirmed cases. [PDF]
Khalifa YM +4 more
europepmc +1 more source
Boronic acid‐based fluorescent hybrids have been used as part of a versatile platform for real‐time metabolic bioimaging across cellular and organismal scales. Including glucose‐responsive imaging in living cells and in an insulin‐deficient vertebrate model, this work opens new opportunities for the development of precision diagnostics, metabolic ...
Haobo Ge +13 more
wiley +1 more source
Oligosaccharides with defined glycosidic bonds drive divergent gut microbial succession and shape unique metabolic profiles. Absolute time‐series profiling with Bayesian generalized Lotka–Volterra modeling identifies bond‐specific microbial responders, while monoculture validation and metaproteomics reveal linkage‐matched transport and cleavage modules.
Xiaoxuan Lu +10 more
wiley +1 more source
WNK1 Phosphorylation Sites in TBC1D1 and TBC1D4 Modulate Cell-Surface Abundance of GLUT1. [PDF]
Henriques AFA +6 more
europepmc +1 more source
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Zheng‐Hao Lai +12 more
wiley +1 more source
Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists. [PDF]
Majeed A, Amir RR, Dar SR, Mahmood A.
europepmc +1 more source
To model a nutrient‐restricted tumor microenvironment, breast cancer cells were adapted to low glucose and glutamine levels. In the adapted cells, BRD4‐driven enhancer activation increases pro‐invasive EDN1 expression, facilitated by ATF3/c‐JUN and reinforced by enhancer RNA.
Poshan Yugal Bhattarai +4 more
wiley +1 more source

